Idiopathic Pulmonary Fibrosis Market Set to Witness Growth with Novel Antifibrotic Therapies and Robust Late-Stage Pipeline by 2036 - DelveInsight | Boehringer Ingelheim, FibroGen, United Therapeutics

The Key Idiopathic Pulmonary Fibrosis Companies in the market include - FibroGen, United Therapeutics, Pliant Therapeutics, Boehringer Ingelheim, Vicore Pharma, Bristol-Myers Squibb, and others.
(Albany, US), September 27, 2026 - DelveInsight's report "Idiopathic Pulmonary Fibrosis Market Insights, Epidemiology, and Market Forecast - 2036" delivers an in-depth understanding of the Idiopathic Pulmonary Fibrosis (IPF) landscape, presenting historical and forecasted epidemiology along with the Idiopathic Pulmonary Fibrosis therapeutics market trends in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.

The report examines current treatment methodologies and algorithms for Idiopathic Pulmonary Fibrosis, assessing the overall market potential, identifying business prospects, and addressing pertinent unmet medical requirements.

Request a sample to unlock the CAGR for the Idiopathic Pulmonary Fibrosis Market Forecast: https://www.delveinsight.com/sample-request/idiopathic-pulmonary-fibrosis-market [https://www.delveinsight.com/sample-request/idiopathic-pulmonary-fibrosis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=akpr]

Some of the key facts of the Idiopathic Pulmonary Fibrosis Market Report:

*
The total market size of Idiopathic Pulmonary Fibrosis in the 7MM was approximately USD 3,300 million in 2023 and is projected to increase during the forecast period (2026-2036).

*
In October 2025, the US FDA approved Boehringer Ingelheim's JASCAYD (nerandomilast) tablets for the treatment of IPF, marking the first new IPF therapy approved in more than a decade.

*
In December 2025, PureTech announced a successful End-of-Phase II meeting with the FDA for deupirfenidone (LYT-100) in IPF, with the Phase III SURPASS-IPF trial on track to be initiated in the first half of 2026 by its founded entity, Celea Therapeutics.

*
In September 2025, PureTech presented new data from the Phase IIb open-label extension study of deupirfenidone (LYT-100), further supporting its strong and durable efficacy and its potential to serve as a new standard of care in IPF.

*
In February 2025, Elixirgen Therapeutics announced that the FDA granted Orphan Drug Designation to EXG-34217, a gene therapy for treating Telomere Biology Disorders (TBDs).

*
According to DelveInsight's 2025 analysis, there were approximately 300,000 diagnosed prevalent cases of IPF across the 7MM.

*
The US accounted for the highest diagnosed prevalent cases of IPF in 2025, with approximately 125,000 cases, representing 41% of the global patient share.

*
Bristol-Myers Squibb's admilparant (BMS-986278), an oral LPA1 antagonist, has Phase III data expected in 2026.

*
Key Idiopathic Pulmonary Fibrosis Companies: FibroGen, United Therapeutics, Pliant Therapeutics, Boehringer Ingelheim, Vicore Pharma, Bristol-Myers Squibb, and others.

*
Key Idiopathic Pulmonary Fibrosis Therapies: Pamrevlumab, Tyvaso (treprostinil), PLN-74809, BI 1015550, VP01 (C21), BMS-986278, JASCAYD (nerandomilast), among others.

Idiopathic Pulmonary Fibrosis Overview

The most prevalent type of pulmonary fibrosis is idiopathic pulmonary fibrosis, which produces scarring (fibrosis) of the lungs. The term "idiopathic" refers to a condition that has no known cause. Scarring produces stiffness in the lungs, making breathing harder. IPF causes irreversible and progressive lung damage that worsens over time, though certain drugs can help slow it down in some circumstances. Lung transplantation is occasionally indicated for persons with IPF.

The signs and symptoms of IPF appear gradually and may not show up until the disease has caused significant lung damage, and are likely to deteriorate over time. Shortness of breath (dyspnea) and dry coughing, which eventually leads to chronic coughing in about 85% of people with IPF, are among the most common signs and symptoms.

To know in detail about the Idiopathic Pulmonary Fibrosis market outlook, drug uptake, treatment scenario, and epidemiology trends, Click here: Idiopathic Pulmonary Fibrosis Market Forecast [https://www.delveinsight.com/report-store/idiopathic-pulmonary-fibrosis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=akpr]

Idiopathic Pulmonary Fibrosis Diagnosis and Treatment Algorithm

Several diagnostic tools are available, and consensus guidelines have been well defined to identify idiopathic pulmonary fibrosis. Pulmonary function tests are performed to assess for restrictive lung disease, characterized by decreased lung volumes (especially decreased forced vital capacity, total lung capacity, and functional residual capacity) and decreased diffusion capacity. When IPF is suspected, laboratory tests to exclude autoimmune disease are also performed. Chest imaging such as x-rays is done, but when not detailed enough to confirm IPF, high-resolution CT (HRCT) of the chest is performed. Patients may also be referred to a surgeon for a lung biopsy under general anesthesia in some instances.

The therapeutic approach to IPF involves both nonpharmacological and pharmacological strategies. The goal of treatment is to slow disease progression, reduce symptoms, prevent acute exacerbations, and prolong survival. Several drugs, including JASCAYD (Boehringer Ingelheim), ESBRIET (Roche), and OFEV (Boehringer Ingelheim), are approved for use in IPF. These therapies help preserve lung function and slow disease progression but do not cure the disease and have not shown a robust, definitive reduction in IPF-related mortality. JASCAYD and OFEV currently lack generics in the market.

Idiopathic Pulmonary Fibrosis Unmet Needs

*
Despite available antifibrotic therapies, significant unmet needs remain in the Idiopathic Pulmonary Fibrosis market due to limited treatment options that can halt or reverse disease progression. Key gaps include:

*
Lack of curative therapies, with limited options that can halt or reverse disease progression

*
Late diagnosis, given that symptoms appear gradually and often only after significant lung damage has occurred

*
High mortality rates despite existing antifibrotic treatment options

*
Treatment limitations including gastrointestinal adverse events, which are the most common reason for discontinuation of both approved antifibrotic drugs

Idiopathic Pulmonary Fibrosis Epidemiology

*
The epidemiology section of the IPF market report offers information on patient populations, including historical and forecasted trends across the 7MM. Key findings include:

*
According to DelveInsight's 2025 analysis, there were approximately 300,000 diagnosed prevalent cases of IPF across the 7MM, a number expected to change by 2036 due to aging populations, heightened awareness, improved diagnostic capabilities, environmental exposures, and rising prevalence of comorbid respiratory conditions.

*
In 2025, the US accounted for the highest diagnosed prevalent cases of IPF among the 7MM, with approximately 125,000 cases; the global patient share was distributed as 41% for the US, 41% for EU4 and UK, and 18% for Japan.

*
In 2025, the UK reported the highest number of cases among EU4 and the UK, with approximately 37,500 cases, followed by Italy, while France recorded the lowest count with approximately 12,300 cases.

*
In 2023, the prevalence of IPF in the 7MM by severity was distributed as mild (FVC >75%) with 55,926 cases, moderate (FVC 50%-75%) with 96,424 cases, and severe (FVC



This release was published on openPR.